Cochrane · systematic review · CD011403
Treatment for hepatitis C virus‐associated mixed cryoglobulinaemia
Montero, N, Favà, A, Rodriguez, E, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 4 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Rituximab compared to no rituximab for hepatitis C virus‐associated mixed cryoglobulinaemia
Population: hepatitis C virus‐associated mixed cryoglobulinaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Skin vasculitis (purpura, cutaneous ulcers or others) at 18 and 24 months: number of affected patients Rituximab vs no rituximab | RR 0.57 [0.28, 1.16] | 2 studies · 78 participants | Moderate |
SCr at 18 months Rituximab vs no rituximab | no estimate extracted | 1 study · 37 participants | Moderate |
Cryocrit at 12 months Rituximab vs no rituximab | no estimate extracted | 2 studies · 41 participants | Low |
Adverse effects ‐ infusion reactions: number of events Rituximab vs no rituximab | RR 4.33 [0.76, 24.75] | 3 studies · 118 participants | Moderate |
Activity outcomes BVAS: from 0 to 63 Rituximab vs no rituximab | no estimate extracted | 2 studies · 81 participants | Moderate Downgraded: risk of bias, inconsistency |